New Guidance for Treating Systemic Sclerosis-associated ILD
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
Read MoreThe US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
Read MoreThe US FDA has approved Boehringer Ingelheim’s Ofev (nintedanib) to treat chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
Read MoreThe FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.
Read MoreThe US FDA has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD).
Read MoreOfev (nintedanib) reduced the annual rate of FVC decline in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Read MoreBoehringer Ingelheim‘s Ofev (nintedanib) preserved the lung function of nine idiopathic pulmonary fibrosis patients waiting for a lung transplant, a study reported. The research, “Safety of nintedanib before lung transplant: an...
Read MoreA clinical trial by Boehringer Ingelheim Pharmaceuticals has begun that will evaluate the effects of Ofev on specific blood biomarkers in idiopathic pulmonary fibrosis patients.
Read MoreNew analyses presented at ATS 2016 further add to the efficacy and safety profile of Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF).
Read MoreBoehringer Ingelheim Pharmaceuticals has announces the results of three new analyses from the PHASE III INPULSIS trials on idiopathic pulmonary fibrosis and OFEV.
Read MoreBoehringer Ingelheim Pharmaceuticals Inc’s New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing by the FDA and granted Priority Review designation.
Read MoreTwo studies have found that two investigational drugs — pirfenidone and nintedanib — had positive effects on patients with idiopathic pulmonary fibrosis (IPF), such as slowing the loss of lung function, reducing mortality, and reducing acute exacerbations.
Read More